These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 7572762)

  • 1. Randomized trial comparing oral ciprofloxacin plus penicillin V with amikacin plus carbenicillin or ceftazidime for empirical treatment of febrile neutropenic cancer patients.
    Velasco E; Costa MA; Martins CA; Nucci M
    Am J Clin Oncol; 1995 Oct; 18(5):429-35. PubMed ID: 7572762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multicenter, randomized trial of ciprofloxacin plus azlocillin versus ceftazidime plus amikacin for empiric treatment of febrile neutropenic patients.
    Flaherty JP; Waitley D; Edlin B; George D; Arnow P; O'Keefe P; Weinstein RA
    Am J Med; 1989 Nov; 87(5A):278S-282S. PubMed ID: 2686429
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
    Metallidis S; Kollaras P; Giannakakis T; Seitanidis B; Kordosis T; Nikolaidis J; Hatzitolios A; Nikolaidis P
    Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monotherapy with intravenous followed by oral high-dose ciprofloxacin versus combination therapy with ceftazidime plus amikacin as initial empiric therapy for granulocytopenic patients with fever.
    Giamarellou H; Bassaris HP; Petrikkos G; Busch W; Voulgarelis M; Antoniadou A; Grouzi E; Zoumbos N
    Antimicrob Agents Chemother; 2000 Dec; 44(12):3264-71. PubMed ID: 11083625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Single-daily ceftriaxone plus amikacin versus thrice-daily ceftazidime plus amikacin as empirical treatment of febrile neutropenia in children with cancer.
    Ariffin H; Arasu A; Mahfuzah M; Ariffin WA; Chan LL; Lin HP
    J Paediatr Child Health; 2001 Feb; 37(1):38-43. PubMed ID: 11168867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monotherapy with piperacillin/tazobactam versus combination therapy with ceftazidime plus amikacin as an empiric therapy for fever in neutropenic cancer patients.
    Hess U; Böhme C; Rey K; Senn HJ
    Support Care Cancer; 1998 Jul; 6(4):402-9. PubMed ID: 9695210
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of cefepime + netilmicin or ceftazidime + amikacin or meropenem monotherapy in febrile neutropenic children with malignancy in Turkey.
    Agaoglu L; Devecioglu O; Anak S; Karakas Z; Yalman N; Biner B; Eryilmaz E; Goksan B; Unuvar A; Agirbasli H; Can M; Bilgen H; Gedikoglu G
    J Chemother; 2001 Jun; 13(3):281-7. PubMed ID: 11450887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral ciprofloxacin in the management of children with cancer with lower risk febrile neutropenia.
    Paganini H; Rodriguez-Brieshcke T; Zubizarreta P; Latella A; Firpo V; Casimir L; Armada A; Fernández C; Cáceres E; Debbag R
    Cancer; 2001 Apr; 91(8):1563-7. PubMed ID: 11301406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Meropenem versus ceftazidime plus amikacin in the treatment of febrile episodes in neutropenic patients: a randomized study.
    de la Cámara R; Figuera A; Sureda A; Hermida G; Verge G; Olalla I; Fernández Rañada JM; Domingo Albos A
    Haematologica; 1997; 82(6):668-75. PubMed ID: 9580087
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monotherapy with meropenem versus combination therapy with ceftazidime plus amikacin as empirical therapy for neutropenic fever in children with malignancy.
    Hung KC; Chiu HH; Tseng YC; Wang JH; Lin HC; Tsai FJ; Peng CT
    J Microbiol Immunol Infect; 2003 Dec; 36(4):254-9. PubMed ID: 14723254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised comparison of oral ofloxacin alone with combination of parenteral antibiotics in neutropenic febrile patients.
    Malik IA; Abbas Z; Karim M
    Lancet; 1992 May; 339(8801):1092-6. PubMed ID: 1349112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cefepime versus ceftazidime + amikacin as empirical therapy for febrile neutropenia in children with cancer: a prospective randomized trial of the treatment efficacy and cost.
    Corapçioglu F; Sarper N
    Pediatr Hematol Oncol; 2005; 22(1):59-70. PubMed ID: 15770833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia in Children.
    Charnas R; Lüthi AR; Ruch W
    Pediatr Infect Dis J; 1997 Apr; 16(4):346-53. PubMed ID: 9109134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empirical antimicrobial therapy in pediatric patients with neutropenia and fever. Risk factors for treatment failure.
    Miranda-Novales MG; Belmont-Martinez L; Villasis-Keever MA; Penagos-Paniagua M; Bernaldez-Rios R; Solorzano-Santos F
    Arch Med Res; 1998; 29(4):331-5. PubMed ID: 9887552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinafloxacin monotherapy (CI-960) versus ceftazidime plus amikacin for empirical treatment of febrile neutropenic cancer patients.
    Glauser MP; Brennscheidt U; Cornely O; Grigg A; Figuera A; Keyserling C; Trostmann U; Welling L; Tack K
    Clin Microbiol Infect; 2002 Jan; 8(1):14-25. PubMed ID: 11906496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Empirical therapy with ceftazidime combined with levofloxacin or once-daily amikacin for febrile neutropenia in patients with neoplasia: a prospective comparative study.
    Samonis G; Koutsounaki E; Karageorgopoulos DE; Mitsikostas P; Kalpadaki C; Bozionelou V; Bompolaki I; Sgouros J; Taktikou V; Falagas ME
    Eur J Clin Microbiol Infect Dis; 2012 Jul; 31(7):1389-98. PubMed ID: 22037822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients.
    Rolston KV; Berkey P; Bodey GP; Anaissie EJ; Khardori NM; Joshi JH; Keating MJ; Holmes FA; Cabanillas FF; Elting L
    Arch Intern Med; 1992 Feb; 152(2):283-91. PubMed ID: 1739355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of meropenem with amikacin plus ceftazidime in the empirical treatment of febrile neutropenia: a prospective randomised multicentre trial in patients without previous prophylactic antibiotics. Meropenem Study Group of Turkey.
    Akova M; Akan H; Korten V; Biberoğlu K; Hayran M; Unal S; Kars A; Kansu E
    Int J Antimicrob Agents; 1999 Sep; 13(1):15-9. PubMed ID: 10563400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A double-blind comparison of empirical oral and intravenous antibiotic therapy for low-risk febrile patients with neutropenia during cancer chemotherapy.
    Freifeld A; Marchigiani D; Walsh T; Chanock S; Lewis L; Hiemenz J; Hiemenz S; Hicks JE; Gill V; Steinberg SM; Pizzo PA
    N Engl J Med; 1999 Jul; 341(5):305-11. PubMed ID: 10423464
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of cefepime and ceftazidime in combination with amikacin in the empirical treatment of high-risk patients with febrile neutropenia: a prospective, randomized, multicenter study.
    Erman M; Akova M; Akan H; Korten V; Ferhanoğlu B; Köksal I; Cetinkaya Y; Uzun O; Unal S;
    Scand J Infect Dis; 2001; 33(11):827-31. PubMed ID: 11760163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.